Celladon Corp., a San Diego-based clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, Friday announced it has appointed Michael Narachi as chairman of the board of directors.
Narachi currently serves as president and CEO of Orexigen Therapeutics Inc. (Nasdaq: OREX).
He has 29 years of biotechnology and pharmaceutical experience across a broad range of functions, including clinical development, commercialization, strategic business development and planning.
Prior to joining Orexigen, Narachi served as chairman, CEO and president of Ren Pharmaceuticals Inc., a private biotechnology company, and executive chairman of the board of Naryx Pharma Inc., a private pharmaceutical company.
3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037